FLSM
Frazier Life Sciences Management Portfolio holdings
AUM
$2.5B
This Quarter Return
+29.18%
1 Year Return
+52.94%
3 Year Return
+530.54%
5 Year Return
–
10 Year Return
–
AUM
$1.61B
AUM Growth
+$1.61B
(+24%)
Cap. Flow
+$160M
Cap. Flow
% of AUM
9.95%
Top 10 Holdings %
Top 10 Hldgs %
66.37%
Holding
50
New
7
Increased
9
Reduced
5
Closed
6
Top Buys
| 1 |
NewAmsterdam Pharma
NAMS
|
$102M |
| 2 |
IMGO
Imago BioSciences, Inc. Common stock
IMGO
|
$36.5M |
| 3 |
VRNA
Verona Pharma
VRNA
|
$18.7M |
| 4 |
VECT
VectivBio Holding AG Ordinary Shares
VECT
|
$11.5M |
| 5 |
KalVista Pharmaceuticals
KALV
|
$11.3M |
Top Sells
| 1 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$26.7M |
| 2 |
FLACU
Frazier Lifesciences Acquisition Corporation Unit
FLACU
|
$15.2M |
| 3 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
$9.31M |
| 4 |
Vaxcyte
PCVX
|
$7.19M |
| 5 |
MacroGenics
MGNX
|
$2.43M |
Sector Composition
| 1 | Healthcare | 99.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
HilleVax
HLVX
$105M
| $163M | 10.15% | 9,758,359 | – | – |
|
|
IMGO
2
DELISTED
Imago BioSciences, Inc. Common stock
IMGO
| $143M | 8.91% | 3,987,207 +1,015,933 | +34% | +$36.5M |
|
3
Arcutis Biotherapeutics
ARQT
$1.86B
| $129M | 7.99% | 8,684,232 | – | – |
|
|
KDNY
4
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $114M | 7.08% | 4,345,559 +80,000 | +2% | +$2.1M |
|
|
5
NewAmsterdam Pharma
NAMS
$2.71B
| $102M | 6.33% | +9,341,551 | New | +$102M |
|
6
Syndax Pharmaceuticals
SNDX
$1.41B
| $94.4M | 5.87% | 3,708,838 +296,000 | +9% | +$7.53M |
|
7
Phathom Pharmaceuticals
PHAT
$864M
| $94.3M | 5.86% | 8,407,152 | – | – |
|
8
Krystal Biotech
KRYS
$4.27B
| $79.2M | 4.92% | 999,737 -18,651 | -2% | -$1.48M |
|
9
Mirum Pharmaceuticals
MIRM
$3.71B
| $75.3M | 4.68% | 3,860,107 +32,326 | +0.8% | +$630K |
|
|
VRNA
10
Verona Pharma
VRNA
$9.16B
| $73.6M | 4.57% | 2,815,720 +716,179 | +34% | +$18.7M |
|
|
11
Vaxcyte
PCVX
$4B
| $67M | 4.17% | 1,397,405 -150,000 | -10% | -$7.19M |
|
12
Rhythm Pharmaceuticals
RYTM
$6.85B
| $55.2M | 3.43% | 1,894,000 | – | – |
|
|
ALLK
13
DELISTED
Allakos
ALLK
| $40.3M | 2.51% | 4,792,000 | – | – |
|
14
AnaptysBio
ANAB
$569M
| $27.9M | 1.73% | 899,700 | – | – |
|
15
Tarsus Pharmaceuticals
TARS
$2.47B
| $26.2M | 1.63% | 1,787,527 | – | – |
|
16
Crinetics Pharmaceuticals
CRNX
$2.92B
| $25.9M | 1.61% | 1,414,823 | – | – |
|
17
Replimune Group
REPL
$422M
| $25.3M | 1.58% | 931,560 +125,293 | +16% | +$3.41M |
|
18
Cogent Biosciences
COGT
$1.69B
| $24.4M | 1.52% | 2,109,154 +35,000 | +2% | +$405K |
|
|
ALPN
19
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $21.9M | 1.36% | 2,985,757 | – | – |
|
|
20
KalVista Pharmaceuticals
KALV
$678M
| $21.9M | 1.36% | 3,238,859 +1,666,667 | +106% | +$11.3M |
|
|
GRTS
21
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $17.8M | 1.11% | 5,162,348 -75,000 | -1% | -$259K |
|
22
Sutro Biopharma
STRO
$72.7M
| $14.4M | 0.89% | 1,776,479 | – | – |
|
23
Acadia Pharmaceuticals
ACAD
$4.38B
| $13.6M | 0.85% | 857,338 | – | – |
|
|
SLN
24
Silence Therapeutics
SLN
$227M
| $13.4M | 0.84% | 881,173 | – | – |
|
25
Trevi Therapeutics
TRVI
$883M
| $12.9M | 0.8% | 6,663,590 +1,260,000 | +23% | +$2.43M |
|